Kiniksa Pharmaceuticals International (KNSA) Short-term Investments (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Short-term Investments for 10 years, with the latest figure at $278.1 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 150.11% year-over-year to $278.1 million; the trailing twelve-month figure through Mar 2026 stood at $278.1 million (up 150.11% YoY), and the FY2025 full-year result was $248.5 million, up 313.81% from the prior year.
• Short-term Investments for Q1 2026 stood at $278.1 million, up from $248.5 million in the prior quarter.
• The five-year high for Short-term Investments was $278.1 million in Q1 2026, with the low at $25.0 million in Q3 2022.
• Historically, Short-term Investments has averaged $111.1 million across 5 years, with a median of $98.4 million in 2023.
• Annual changes were most pronounced in 2022 — Short-term Investments jumped 39068.1% — and 2024, when it plunged 38.99%.
• Kiniksa Pharmaceuticals International's Short-term Investments stood at $67.9 million in 2022, then surged by 44.96% to $98.4 million in 2023, then plunged by 38.99% to $60.0 million in 2024, then soared by 313.81% to $248.5 million in 2025, then climbed by 11.94% to $278.1 million in 2026.
• The last three Short-term Investments figures came in at $278.1 million (Q1 2026), $248.5 million (Q4 2025), and $177.2 million (Q3 2025), per Business Quant data.